undamentalytics Newsletter
Sign in

Iovance Biotherapeutics, Inc. balance sheet

At the end of fiscal 2025, Iovance Biotherapeutics, Inc. had total assets of $913m, total liabilities of $215m and shareholders' equity of $699m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents20453410714582115116163111
Receivables——————06982102
Inventory——————10525256
Total current assets2045104170149475308457443464
Total assets2047106172155481780910913916
Accounts payable01111333282226
Total current liabilities22251014110122138107
Long-term debt——————11——
Total debt00000011—0
Total liabilities————1015196200215179
Shareholders' equity1845104167145466585710699736
Shares outstanding——49m62m73m—256m305m412m453m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ARVN vs IOVAADPT vs IOVAIOVA vs VCEL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Iovance Biotherapeutics, Inc.